As a momentary conclusion, survodutide, cotadutide, and efinopegdutide dual GLP-1R/GCGR co-agonists display potential benefits in MASH-related fibrosis and cirrhosis, while pemvidutide and mazdutide need more investigations in this area. Here, GCGR is linked to metabolic dysfunction-associated steatohepatitis.